These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2919553

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of the angiotensin-converting-enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, in dog.
    King JN, Maurer M, Morrison CA, Mauron C, Kaiser G.
    Xenobiotica; 1997 Aug; 27(8):819-29. PubMed ID: 9293618
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
    Kitagawa H, Eguchi T, Kitoh K, Ohba Y, Kondo M, Nakano M, Sasaki Y.
    J Vet Med Sci; 2000 Feb; 62(2):179-85. PubMed ID: 10720188
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs.
    King JN, Mauron C, Kaiser G.
    Am J Vet Res; 1995 Dec; 56(12):1620-8. PubMed ID: 8599524
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
    Kaiser G, Ackermann R, Brechbühler S, Dieterle W.
    Biopharm Drug Dispos; 1989 Dec; 10(4):365-76. PubMed ID: 2758102
    [Abstract] [Full Text] [Related]

  • 9. Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats.
    King JN, Strehlau G, Wernsing J, Brown SA.
    J Vet Pharmacol Ther; 2002 Oct; 25(5):371-8. PubMed ID: 12423228
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
    Waldmeier F, Kaiser G, Ackermann R, Faigle JW, Wagner J, Barner A, Lasseter KC.
    Xenobiotica; 1991 Feb; 21(2):251-61. PubMed ID: 2058180
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
    Lefebvre HP, Laroute V, Concordet D, Toutain PL.
    J Vet Intern Med; 1999 Feb; 13(1):21-7. PubMed ID: 10052059
    [Abstract] [Full Text] [Related]

  • 19. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P.
    N Engl J Med; 1996 Apr 11; 334(15):939-45. PubMed ID: 8596594
    [Abstract] [Full Text] [Related]

  • 20. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: case of enalapril and benazepril in dogs.
    Toutain PL, Lefebvre HP, Laroute V.
    J Pharmacol Exp Ther; 2000 Mar 11; 292(3):1094-103. PubMed ID: 10688628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.